Section Arrow
HELP.NASDAQ
- Cybin Inc
Quotes are at least 15-min delayed:2026/06/10 19:21 EDT
After Hours
Last
 3.94
+0.07 (+1.81%)
Bid
3.87
Ask
4.07
High 3.94 
Low 3.87 
Volume 1.10K 
Regular Hours (Closed)
Last
 3.87
-0.05 (-1.28%)
Day High 
4.05 
Prev. Close
3.92 
1-M High
5.35 
Volume 
403.62K 
Bid
3.87
Ask
4.07
Day Low
3.8539 
Open
3.9 
1-M Low
3.76 
Market Cap 
195.58M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 4.35 
20-SMA 4.51 
50-SMA 4.97 
52-W High 9.83 
52-W Low 3.76 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.30/-2.62
Enterprise Value
195.58M
Balance Sheet
Book Value Per Share
5.49
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ADTXAditxt Inc.0.0185-0.0104-35.99%-- 
After Hours 0.0192 +0.0007 +3.78%
GOSSGossamer Bio0.156-0.004-2.50%-- 
After Hours 0.1594 +0.0034 +2.18%
OTLKOutlook Therapeutics0.89+0.1853+26.29%-- 
After Hours 0.95 +0.06 +6.74%
RXRXRecursion Pharmaceuticals3.04-0.18-5.59%-- 
After Hours 3.03 -0.01 -0.33%
GERNGeron Corp1.1-0.02-1.79%-- 
After Hours 1.11 +0.01 +0.91%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.